Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: The Losartan Intervention for Endpoint reduction in hypertension study

Jorge Kizer, Björn Dahlöf, Sverre E. Kjeldsen, Stevo Julius, Gareth Beevers, Ulf De Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristianson, Ole Lederballe-Pedersen, Lars H. Lindholm, Markka S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Kristian Wachtell, Jonathan M. Edelman, Steven M. Snapinn, Katherine E. Harris, Richard B. Devereux

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the β-blocker atenolol. We conducted secondary analyses in LIFE to determine the extent to which the cerebrovascular benefits of losartan apply to different clinical subgroups and stroke subtypes and to assess the dependence of these benefits on baseline and time-varying covariates. Among 9193 hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy, random allocation to losartan-based treatment lowered the risk of fatal (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.43 to 0.96; P=0.032) and atherothrombotic stroke (HR, 0.72; 95% CI, 0.59 to 0.88; P=0.001) compared with atenolol-based therapy. Although comparable risk reductions occurred for hemorrhagic and embolic stroke, these were not statistically significant. The number of neurological deficits per stroke was similar, but there were fewer strokes in the losartan group for nearly every level of stroke severity. Effects were consistent in all clinical subgroups except for those defined by age and ethnicity. The benefits of losartan on all strokes were independent of baseline and time-varying risk factors, including blood pressure. The number needed to treat for 5 years to prevent 1 stroke was 54 for the average participant, declining to 25, 24, and 9 for patients with cerebrovascular disease, isolated systolic hypertension, and atrial fibrillation, respectively. In conclusion, substantial cerebrovascular benefit could be realized with the institution of losartan-based therapy over conventional therapy among hypertensive patients with left ventricular hypertrophy across the spectrum of cardiovascular risk.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalHypertension
Volume45
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Atenolol
Losartan
Cardiomegaly
Stroke
Hypertension
Left Ventricular Hypertrophy
Therapeutics
Confidence Intervals
Angiotensin II Type 1 Receptor Blockers
Cerebrovascular Disorders
Numbers Needed To Treat
Risk Reduction Behavior
Random Allocation
Atrial Fibrillation
Blood Pressure

Keywords

  • Angiotensin antagonists
  • Clinical trials
  • Drug therapy
  • Hypertrophy
  • Population
  • Stroke

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol : The Losartan Intervention for Endpoint reduction in hypertension study. / Kizer, Jorge; Dahlöf, Björn; Kjeldsen, Sverre E.; Julius, Stevo; Beevers, Gareth; De Faire, Ulf; Fyhrquist, Frej; Ibsen, Hans; Kristianson, Krister; Lederballe-Pedersen, Ole; Lindholm, Lars H.; Nieminen, Markka S.; Omvik, Per; Oparil, Suzanne; Wedel, Hans; Wachtell, Kristian; Edelman, Jonathan M.; Snapinn, Steven M.; Harris, Katherine E.; Devereux, Richard B.

In: Hypertension, Vol. 45, No. 1, 01.2005, p. 46-52.

Research output: Contribution to journalArticle

Kizer, J, Dahlöf, B, Kjeldsen, SE, Julius, S, Beevers, G, De Faire, U, Fyhrquist, F, Ibsen, H, Kristianson, K, Lederballe-Pedersen, O, Lindholm, LH, Nieminen, MS, Omvik, P, Oparil, S, Wedel, H, Wachtell, K, Edelman, JM, Snapinn, SM, Harris, KE & Devereux, RB 2005, 'Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: The Losartan Intervention for Endpoint reduction in hypertension study', Hypertension, vol. 45, no. 1, pp. 46-52. https://doi.org/10.1161/01.HYP.0000151324.05355.1c
Kizer, Jorge ; Dahlöf, Björn ; Kjeldsen, Sverre E. ; Julius, Stevo ; Beevers, Gareth ; De Faire, Ulf ; Fyhrquist, Frej ; Ibsen, Hans ; Kristianson, Krister ; Lederballe-Pedersen, Ole ; Lindholm, Lars H. ; Nieminen, Markka S. ; Omvik, Per ; Oparil, Suzanne ; Wedel, Hans ; Wachtell, Kristian ; Edelman, Jonathan M. ; Snapinn, Steven M. ; Harris, Katherine E. ; Devereux, Richard B. / Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol : The Losartan Intervention for Endpoint reduction in hypertension study. In: Hypertension. 2005 ; Vol. 45, No. 1. pp. 46-52.
@article{c8cd3f516cab4ffcbc9819b82372c04d,
title = "Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: The Losartan Intervention for Endpoint reduction in hypertension study",
abstract = "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the β-blocker atenolol. We conducted secondary analyses in LIFE to determine the extent to which the cerebrovascular benefits of losartan apply to different clinical subgroups and stroke subtypes and to assess the dependence of these benefits on baseline and time-varying covariates. Among 9193 hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy, random allocation to losartan-based treatment lowered the risk of fatal (hazard ratio [HR], 0.65; 95{\%} confidence interval [CI], 0.43 to 0.96; P=0.032) and atherothrombotic stroke (HR, 0.72; 95{\%} CI, 0.59 to 0.88; P=0.001) compared with atenolol-based therapy. Although comparable risk reductions occurred for hemorrhagic and embolic stroke, these were not statistically significant. The number of neurological deficits per stroke was similar, but there were fewer strokes in the losartan group for nearly every level of stroke severity. Effects were consistent in all clinical subgroups except for those defined by age and ethnicity. The benefits of losartan on all strokes were independent of baseline and time-varying risk factors, including blood pressure. The number needed to treat for 5 years to prevent 1 stroke was 54 for the average participant, declining to 25, 24, and 9 for patients with cerebrovascular disease, isolated systolic hypertension, and atrial fibrillation, respectively. In conclusion, substantial cerebrovascular benefit could be realized with the institution of losartan-based therapy over conventional therapy among hypertensive patients with left ventricular hypertrophy across the spectrum of cardiovascular risk.",
keywords = "Angiotensin antagonists, Clinical trials, Drug therapy, Hypertrophy, Population, Stroke",
author = "Jorge Kizer and Bj{\"o}rn Dahl{\"o}f and Kjeldsen, {Sverre E.} and Stevo Julius and Gareth Beevers and {De Faire}, Ulf and Frej Fyhrquist and Hans Ibsen and Krister Kristianson and Ole Lederballe-Pedersen and Lindholm, {Lars H.} and Nieminen, {Markka S.} and Per Omvik and Suzanne Oparil and Hans Wedel and Kristian Wachtell and Edelman, {Jonathan M.} and Snapinn, {Steven M.} and Harris, {Katherine E.} and Devereux, {Richard B.}",
year = "2005",
month = "1",
doi = "10.1161/01.HYP.0000151324.05355.1c",
language = "English (US)",
volume = "45",
pages = "46--52",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol

T2 - The Losartan Intervention for Endpoint reduction in hypertension study

AU - Kizer, Jorge

AU - Dahlöf, Björn

AU - Kjeldsen, Sverre E.

AU - Julius, Stevo

AU - Beevers, Gareth

AU - De Faire, Ulf

AU - Fyhrquist, Frej

AU - Ibsen, Hans

AU - Kristianson, Krister

AU - Lederballe-Pedersen, Ole

AU - Lindholm, Lars H.

AU - Nieminen, Markka S.

AU - Omvik, Per

AU - Oparil, Suzanne

AU - Wedel, Hans

AU - Wachtell, Kristian

AU - Edelman, Jonathan M.

AU - Snapinn, Steven M.

AU - Harris, Katherine E.

AU - Devereux, Richard B.

PY - 2005/1

Y1 - 2005/1

N2 - The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the β-blocker atenolol. We conducted secondary analyses in LIFE to determine the extent to which the cerebrovascular benefits of losartan apply to different clinical subgroups and stroke subtypes and to assess the dependence of these benefits on baseline and time-varying covariates. Among 9193 hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy, random allocation to losartan-based treatment lowered the risk of fatal (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.43 to 0.96; P=0.032) and atherothrombotic stroke (HR, 0.72; 95% CI, 0.59 to 0.88; P=0.001) compared with atenolol-based therapy. Although comparable risk reductions occurred for hemorrhagic and embolic stroke, these were not statistically significant. The number of neurological deficits per stroke was similar, but there were fewer strokes in the losartan group for nearly every level of stroke severity. Effects were consistent in all clinical subgroups except for those defined by age and ethnicity. The benefits of losartan on all strokes were independent of baseline and time-varying risk factors, including blood pressure. The number needed to treat for 5 years to prevent 1 stroke was 54 for the average participant, declining to 25, 24, and 9 for patients with cerebrovascular disease, isolated systolic hypertension, and atrial fibrillation, respectively. In conclusion, substantial cerebrovascular benefit could be realized with the institution of losartan-based therapy over conventional therapy among hypertensive patients with left ventricular hypertrophy across the spectrum of cardiovascular risk.

AB - The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the β-blocker atenolol. We conducted secondary analyses in LIFE to determine the extent to which the cerebrovascular benefits of losartan apply to different clinical subgroups and stroke subtypes and to assess the dependence of these benefits on baseline and time-varying covariates. Among 9193 hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy, random allocation to losartan-based treatment lowered the risk of fatal (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.43 to 0.96; P=0.032) and atherothrombotic stroke (HR, 0.72; 95% CI, 0.59 to 0.88; P=0.001) compared with atenolol-based therapy. Although comparable risk reductions occurred for hemorrhagic and embolic stroke, these were not statistically significant. The number of neurological deficits per stroke was similar, but there were fewer strokes in the losartan group for nearly every level of stroke severity. Effects were consistent in all clinical subgroups except for those defined by age and ethnicity. The benefits of losartan on all strokes were independent of baseline and time-varying risk factors, including blood pressure. The number needed to treat for 5 years to prevent 1 stroke was 54 for the average participant, declining to 25, 24, and 9 for patients with cerebrovascular disease, isolated systolic hypertension, and atrial fibrillation, respectively. In conclusion, substantial cerebrovascular benefit could be realized with the institution of losartan-based therapy over conventional therapy among hypertensive patients with left ventricular hypertrophy across the spectrum of cardiovascular risk.

KW - Angiotensin antagonists

KW - Clinical trials

KW - Drug therapy

KW - Hypertrophy

KW - Population

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=19944428946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944428946&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000151324.05355.1c

DO - 10.1161/01.HYP.0000151324.05355.1c

M3 - Article

C2 - 15583076

AN - SCOPUS:19944428946

VL - 45

SP - 46

EP - 52

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -